267 related articles for article (PubMed ID: 32343628)
1. Can the Adoption of Hypofractionation Guidelines Expand Global Radiotherapy Access? An Analysis for Breast and Prostate Radiotherapy.
Irabor OC; Swanson W; Shaukat F; Wirtz J; Mallum AA; Ngoma T; Elzawawy A; Nguyen P; Incrocci L; Ngwa W
JCO Glob Oncol; 2020 Apr; 6():667-678. PubMed ID: 32343628
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and Benefits.
Ray KJ; Sibson NR; Kiltie AE
Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):420-6. PubMed ID: 25752244
[TBL] [Abstract][Full Text] [Related]
3. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated radiotherapy in the real-world setting: An international ESTRO-GIRO survey.
Rodin D; Tawk B; Mohamad O; Grover S; Moraes FY; Yap ML; Zubizarreta E; Lievens Y
Radiother Oncol; 2021 Apr; 157():32-39. PubMed ID: 33453312
[TBL] [Abstract][Full Text] [Related]
5. Practical considerations for prostate hypofractionation in the developing world.
Yan M; Gouveia AG; Cury FL; Moideen N; Bratti VF; Patrocinio H; Berlin A; Mendez LC; Moraes FY
Nat Rev Urol; 2021 Nov; 18(11):669-685. PubMed ID: 34389825
[TBL] [Abstract][Full Text] [Related]
6. Introduction of ultra-hypofractionation in breast cancer: Implications for costs and resource use.
Busschaert SL; Kimpe E; Barbé K; De Ridder M; Putman K
Radiother Oncol; 2024 Jan; 190():110010. PubMed ID: 37956888
[TBL] [Abstract][Full Text] [Related]
7. Cost Minimization Analysis of Hypofractionated Radiotherapy.
Yaremko HL; Locke GE; Chow R; Lock M; Dinniwell R; Yaremko BP
Curr Oncol; 2021 Jan; 28(1):716-725. PubMed ID: 33573158
[TBL] [Abstract][Full Text] [Related]
8. Practical Guidelines on Implementing Hypofractionated Radiotherapy for Prostate Cancer in Africa.
Swanson W; Samba RN; Lavelle M; Elzawawy A; Sajo E; Ngwa W; Incrocci L
Front Oncol; 2021; 11():725103. PubMed ID: 34926247
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionation Adoption in Prostate Cancer Radiotherapy: Results of an International Survey.
Sabbagh A; Weiss J; Tawk B; Mohammed MA; Abdulbaki H; Moraes FY; Grover S; Yap ML; Zubizarreta E; Lievens Y; Rodin D; Mohamad O
JCO Glob Oncol; 2023 Jun; 9():e2300046. PubMed ID: 37319396
[TBL] [Abstract][Full Text] [Related]
10. Expanding radiotherapy access in Sub-Saharan Africa: an analysis of travel burdens and patient-related benefits of hypofractionation.
Patel S; Olatunji E; Mallum A; Benjika BB; Joseph AO; Joseph S; Lasebikan N; Mahuna H; Ngoma M; Ngoma TA; Nnko G; Onwualu C; Vorster M; Ngwa W
Front Oncol; 2023; 13():1136357. PubMed ID: 37143940
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionation for clinically localized prostate cancer.
Hickey BE; James ML; Daly T; Soh FY; Jeffery M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated radiotherapy recommendations for localized prostate cancer in Brasil.
Palhares DMF; Pimentel LCF; Castilho MS; Costa ABD; Reisner ML; Kuhnen FQ; Pássaro A; Leite ETT; Faustino FLC; Obst FM; Costa FNBBF; Pioner GT; Carvalho ÍT; Silva JLFD; Morikawa LKK; Zanuncio PHDR; Hanriot RM; Rosa AA
Rev Assoc Med Bras (1992); 2021 Jan; 67(1):7-18. PubMed ID: 34161478
[TBL] [Abstract][Full Text] [Related]
13. Is moderate hypofractionation accepted as a new standard of care in north america for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists.
McClelland S; Sandler KA; Degnin C; Chen Y; Hung AY; Mitin TE
Int Braz J Urol; 2019; 45(2):273-287. PubMed ID: 30676300
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy resources in Latin America and the Caribbean: a review of current and projected needs based on International Atomic Energy Agency data.
Elbanna M; Pynda Y; Kalinchuk O; Rosa A; Abdel-Wahab M
Lancet Oncol; 2023 Sep; 24(9):e376-e384. PubMed ID: 37657478
[TBL] [Abstract][Full Text] [Related]
15. Cost-containment in hypofractionated radiation therapy: a literature review.
Hunter D; Mauldon E; Anderson N
J Med Radiat Sci; 2018 Jun; 65(2):148-157. PubMed ID: 29532613
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated Radiotherapy for Localized Prostate Cancer: When and for Whom?
Roy S; Morgan SC
Curr Urol Rep; 2019 Jul; 20(9):53. PubMed ID: 31359187
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer.
Teh BS; Lewis GD; Mai W; Pino R; Ishiyama H; Butler EB
Cancer Commun (Lond); 2018 Apr; 38(1):11. PubMed ID: 29764515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
